Petra Reinke

List of Publications by Year
in descending order

213 papers	12,068 citations	30070 54 h-index	32842 100 g-index
224 all docs	224 docs citations	224 times ranked	12714 citing authors

#	Article	IF	Citations
1	Intramuscular and intratendinous placentaâ€derived mesenchymal stromalâ€like cell treatment of a chronic quadriceps tendon rupture. Journal of Cachexia, Sarcopenia and Muscle, 2022, 13, 434-442.	7.3	3
2	Advanced Therapy Medicinal Products' Translation in Europe: A Developers' Perspective. Frontiers in Medicine, 2022, 9, 757647.	2.6	12
3	Adoptive transfer of exÂvivo expanded regulatory T cells improves immune cell engraftment and therapy-refractory chronic GvHD. Molecular Therapy, 2022, 30, 2298-2314.	8.2	16
4	Study Design: Human Leukocyte Antigen Class I Molecule Aâ^—02-Chimeric Antigen Receptor Regulatory T Cells in Renal Transplantation. Kidney International Reports, 2022, 7, 1258-1267.	0.8	22
5	Tacrolimus-resistant SARS-CoV-2-specific T cell products to prevent and treat severe COVID-19 in immunosuppressed patients. Molecular Therapy - Methods and Clinical Development, 2022, 25, 52-73.	4.1	11
6	Early prediction of renal graft function: Analysis of a multi-center, multi-level data set. Current Research in Translational Medicine, 2022, 70, 103334.	1.8	2
7	Human iPSC-Derived Renal Cells Change Their Immunogenic Properties during Maturation: Implications for Regenerative Therapies. Cells, 2022, 11, 1328.	4.1	2
8	CRISPR-Cas9-Edited Tacrolimus-Resistant Antiviral T Cells for Advanced Adoptive Immunotherapy in Transplant Recipients. Molecular Therapy, 2021, 29, 32-46.	8.2	27
9	The intratumoral CXCR3 chemokine system is predictive of chemotherapy response in human bladder cancer. Science Translational Medicine, 2021, 13, .	12.4	35
10	Preformed T cell alloimmunity and HLA eplet mismatch to guide immunosuppression minimization with tacrolimus monotherapy in kidney transplantation: Results of the CELLIMIN trial. American Journal of Transplantation, 2021, 21, 2833-2845.	4.7	27
11	Reduction of immunosuppression combined with whole-brain radiotherapy and concurrent systemic rituximab is an effective yet toxic treatment of primary central nervous system post-transplant lymphoproliferative disorder (pCNS-PTLD): 14 cases from the prospective German PTLD registry. Annals of Hematology, 2021, 100, 2043-2050.	1.8	4
12	Detection of pre-existing SARS-CoV-2-reactive T cells in unexposed renal transplant patients. Journal of Nephrology, 2021, 34, 1025-1037.	2.0	6
13	Generation of 20 human induced pluripotent stem cell lines from patients with focal segmental glomerulosclerosis (FSGS). Stem Cell Research, 2021, 54, 102406.	0.7	2
14	Bio-instructive hydrogel expands the paracrine potency of mesenchymal stem cells. Biofabrication, 2021, 13, 045002.	7.1	32
15	Risk factors for Epsteinâ€“Barr virus reactivation after renal transplantation: Results of a large, multiâ€centre study. Transplant International, 2021, 34, 1680-1688.	1.6	5
16	An Individual Patient's â€œBodyâ€•on Chipsâ€”How Organismoid Theory Can Translate Into Your Personal Precision Therapy Approach. Frontiers in Medicine, 2021, 8, 728866.	2.6	6
17	Cyclosporine A but Not Corticosteroids Support Efficacy of Ex Vivo Expanded, Adoptively Transferred Human Tregs in GvHD. Frontiers in Immunology, 2021, 12, 716629.	4.8	4
18	RESTORE Survey on the Public Perception of Advanced Therapies and ATMPs in Europeâ€”Why the European Union Should Invest More!. Frontiers in Medicine, 2021, 8, 739987.	2.6	7

#	Article	IF	Citations
19	Strong Expansion of Human Regulatory T Cells for Adoptive Cell Therapy Results in Epigenetic Changes Which May Impact Their Survival and Function. Frontiers in Cell and Developmental Biology, 2021, 9, 751590.	3.7	10
20	Freezing Medium Containing 5% DMSO Enhances the Cell Viability and Recovery Rate After Cryopreservation of Regulatory T Cell Products ex vivo and in vivo. Frontiers in Cell and Developmental Biology, 2021, 9, 750286.	3.7	10
21	Preformed donorâ€reactive T cells that persist after ABO desensitization predict severe T cellâ€mediated rejection after living donor kidney transplantation â€“ a retrospective study. Transplant International, 2020, 33, 288-297.	1.6	5
22	Placenta-Derived Cell Therapy to Treat Patients With Respiratory Failure Due to Coronavirus Disease 2019. , 2020, 2, e0207.		13
23	The role of soluble mediators in the clinical course of EBV infection and B cell homeostasis after kidney transplantation. Scientific Reports, 2020, 10, 19594.	3.3	4
24	Regulatory T cells for minimising immune suppression in kidney transplantation: phase I/IIa clinical trial. BMJ, The, 2020, 371, m3734.	6.0	101
25	Treatment of Anti-HLA Donor-Specific Antibodies Results in Increased Infectious Complications and Impairs Survival after Liver Transplantation. Journal of Clinical Medicine, 2020, 9, 3986.	2.4	2
26	MSC Therapies for COVID-19: Importance of Patient Coagulopathy, Thromboprophylaxis, Cell Product Quality and Mode of Delivery for Treatment Safety and Efficacy. Frontiers in Immunology, 2020, 11, 1091.	4.8	128
27	Adult Tissue Extracellular Matrix Determines Tissue Specification of Human iPSCâ€Derived Embryonic Stage Mesodermal Precursor Cells. Advanced Science, 2020, 7, 1901198.	11.2	33
28	Editorial comment: variables affecting the presence of mesenchymal stromal cells in the peripheral blood and their relationship with apheresis product. British Journal of Haematology, 2020, 189, 593-596.	2.5	5
29	Toward an Optimized Process for Clinical Manufacturing of CAR-Treg Cell Therapy. Trends in Biotechnology, 2020, 38, 1099-1112.	9.3	68
30	Dialysis therapy is associated with peripheral marginal zone B-cell augmentation. Transplant Immunology, 2020, 60, 101289.	1.2	0
31	Super-Treg: Toward a New Era of Adoptive Treg Therapy Enabled by Genetic Modifications. Frontiers in Immunology, 2020, 11, 611638.	4.8	26
32	Regulatory cell therapy in kidney transplantation (The ONE Study): a harmonised design and analysis of seven non-randomised, single-arm, phase 1/2A trials. Lancet, The, 2020, 395, 1627-1639.	13.7	266
33	Kidney transplant monitoring by urinary flow cytometry: Biomarker combination of T cells, renal tubular epithelial cells, and podocalyxin-positive cells detects rejection. Scientific Reports, 2020, 10, 796.	3.3	20
34	Two decades of the Eurotransplant Senior Program: the gender gap in mortality impacts patient survival after kidney transplantation. CKJ: Clinical Kidney Journal, 2020, 13, 1091-1100.	2.9	14
35	Sex-Associated Differences in Cytomegalovirus Prevention: Prophylactic Strategy is Potentially Associated With a Strong Kidney Function Impairment in Female Renal Transplant Patients. Frontiers in Pharmacology, 2020, 11, 534681.	3.5	3
36	Effects of expanded allocation programmes and organ and recipient quality metrics on transplantâ€related costs in kidney transplantation â€“ an institutional analysis. Transplant International, 2019, 32, 1074-1084.	1.6	6

#	Article	IF	Citations
37	Intensive blood pressure control is associated with improved patient and graft survival after renal transplantation. Scientific Reports, 2019, 9, 10507.	3.3	15
38	Preformed Donor-Specific HLA Antibodies in Living and Deceased Donor Transplantation. Clinical Journal of the American Society of Nephrology: CJASN, 2019, 14, 1056-1066.	4.5	49
39	Intravascular Mesenchymal Stromal/Stem Cell Therapy Product Diversification: Time for New Clinical Guidelines. Trends in Molecular Medicine, 2019, 25, 149-163.	6.7	288
40	VEGF â€“ Supplemented extracellular matrix is sufficient to induce endothelial differentiation of human iPSC. Biomaterials, 2019, 216, 119283.	11.4	36
41	Comprehensive Characterization of a Next-Generation Antiviral T-Cell Product and Feasibility for Application in Immunosuppressed Transplant Patients. Frontiers in Immunology, 2019, 10, 1148.	4.8	9
42	A novel approach reveals that HLA class 1 single antigen bead-signatures provide a means of high-accuracy pre-transplant risk assessment of acute cellular rejection in renal transplantation. BMC Immunology, 2019, 20, 11.	2.2	14
43	The Role of Pre-existing Cross-Reactive Central Memory CD4 T-Cells in Vaccination With Previously Unseen Influenza Strains. Frontiers in Immunology, 2019, 10, 593.	4.8	27
44	BKV Clearance Time Correlates With Exhaustion State and T-Cell Receptor Repertoire Shape of BKV-Specific T-Cells in Renal Transplant Patients. Frontiers in Immunology, 2019, 10, 767.	4.8	18
45	Generating Multiple Kidney Progenitors and Cell Types from Human Pluripotent Stem Cells. Methods in Molecular Biology, 2019, 1926, 103-115.	0.9	5
46	The Value of a Rapid Test of Human Regulatory T Cell Function Needs to be Revised. Frontiers in Immunology, 2019, 10, 150.	4.8	3
47	Multi-Parameter Analysis of Biobanked Human Bone Marrow Stromal Cells Shows Little Influence for Donor Age and Mild Comorbidities on Phenotypic and Functional Properties. Frontiers in Immunology, 2019, 10, 2474.	4.8	64
48	Mechanisms of Immune Tolerance in Liver Transplantation-Crosstalk Between Alloreactive T Cells and Liver Cells With Therapeutic Prospects. Frontiers in Immunology, 2019, 10, 2667.	4.8	27
49	Heterologous Cytomegalovirus and Allo-Reactivity by Shared T Cell Receptor Repertoire in Kidney Transplantation. Frontiers in Immunology, 2019, 10, 2549.	4.8	20
50	The TreaT-Assay: A Novel Urine-Derived Donor Kidney Cell-Based Assay for Prediction of Kidney Transplantation Outcome. Scientific Reports, 2019, 9, 19037.	3.3	5
51	Cytotoxic Effects of Rabbit Anti-thymocyte Globulin Preparations on Primary Human Thymic Epithelial Cells. Transplantation, 2019, 103, 2234-2244.	1.0	5
52	The Identity Card of T Cellsâ€"Clinical Utility of T-cell Receptor Repertoire Analysis in Transplantation. Transplantation, 2019, 103, 1544-1555.	1.0	12
53	High prevalence of Streptococcus pyogenes Cas9-reactive T cells within the adult human population. Nature Medicine, 2019, 25, 242-248.	30.7	280
54	Parallel generation of easily selectable multiple nephronal cell types from human pluripotent stem cells. Cellular and Molecular Life Sciences, 2019, 76, 179-192.	5.4	15

#	Article	IF	Citations
55	Factors and outcomes in association with sepsis differ between simultaneous pancreas/kidney and single kidney transplant recipients. Transplant Infectious Disease, 2018, 20, e12848.	1.7	5
56	Transplantectomy is associated with presensitization with donor-reactive T cells and graft failure after kidney retransplantation: a cohort study. Nephrology Dialysis Transplantation, 2018, 33, 889-896.	0.7	12
57	Five-year outcomes in kidney transplant patients randomized to everolimus with cyclosporine withdrawal or low-exposure cyclosporine versus standard therapy. American Journal of Transplantation, 2018, 18, 2965-2976.	4.7	11
58	Evaluation of adherence and tolerability of prolongedâ€•release tacrolimus (Advagrafâ„¢) in kidney transplant patients in Germany: A multicenter, noninterventional study. Clinical Transplantation, 2018, 32, e13142.	1.6	18
59	Valganciclovir Prophylaxis Versus Preemptive Therapy in Cytomegalovirus-Positive Renal Allograft Recipients. Transplantation, 2018, 102, 876-882.	1.0	53
60	End-of-Treatment Positron Emission Tomography After Uniform First-Line Therapy of B-Cell Posttransplant Lymphoproliferative Disorder Identifies Patients at Low Risk of Relapse in the Prospective German PTLD Registry. Transplantation, 2018, 102, 868-875.	1.0	26
61	Prevalence and Clinical Correlates of Chronic Hepatitis E Infection in German Renal Transplant Recipients With Elevated Liver Enzymes. Transplantation Direct, 2018, 4, e341.	1.6	23
62	Onset and progression of diabetes in kidney transplant patients receiving everolimus or cyclosporine therapy: an analysis of two randomized, multicenter trials. BMC Nephrology, 2018, 19, 237.	1.8	14
63	Rescue from lethal acute radiation syndrome (ARS) with severe weight loss by secretome of intramuscularly injected human placental stromal cells. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 1079-1092.	7.3	25
64	Immunomodulatory placentalâ€•expanded, mesenchymal stromal cells improve muscle function following hip arthroplasty. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 880-897.	7.3	53
65	Immunosuppression Is Associated With Clinical Features and Relapse Risk of B Cell Posttransplant Lymphoproliferative Disorder: A Retrospective Analysis Based on the Prospective, International, Multicenter PTLD-1 Trials. Transplantation, 2018, 102, 1914-1923.	1.0	11
66	ExÂvivo expanded natural regulatory T cells from patients with end-stage renal disease or kidney transplantation are useful for autologous cell therapy. Kidney International, 2018, 93, 1452-1464.	5.2	20
67	Differential T cell response against BK virus regulatory and structural antigens: A viral dynamics modelling approach. PLoS Computational Biology, 2018, 14, e1005998.	3.2	13
68	Immunomodulation by adoptive regulatory Tâ€•cell transfer improves Coxsackievirus B3â€•induced myocarditis. FASEB Journal, 2018, 32, 6066-6078.	0.5	42
69	BKV, CMV, and EBV Interactions and their Effect on Graft Function One Year Post-Renal Transplantation: Results from a Large Multi-Centre Study. EBioMedicine, 2018, 34, 113-121.	6.1	66
70	Histological findings to five years after early conversion of kidney transplant patients from cyclosporine to everolimus: an analysis from the randomized ZEUS study. BMC Nephrology, 2018, 19, 154.	1.8	3
71	Immunoadsorption to remove ÃŸ2 adrenergic receptor antibodies in Chronic Fatigue Syndrome CFS/ME. PLoS ONE, 2018, 13, e0193672.	2.5	83
72	Response to Rituximab Induction Is a Predictive Marker in B-Cell Post-Transplant Lymphoproliferative Disorder and Allows Successful Stratification Into Rituximab or R-CHOP Consolidation in an International, Prospective, Multicenter Phase II Trial. Journal of Clinical Oncology, 2017, 35, 536-543.	1.6	168

#	Article	IF	Citations
73	Increased alloreactivity and adverse outcomes in obese kidney transplant recipients are limited to those with diabetes mellitus. Transplant Immunology, 2017, 40, 8-16.	1.2	8
74	Comparative characterization of decellularized renal scaffolds for tissue engineering. Biomedical Materials (Bristol), 2017, 12, 045005.	3.3	35
75	Diabetic kidney transplant recipients: Impaired infection control and increased alloreactivity. Clinical Transplantation, 2017, 31, e12986.	1.6	8
76	CMV-Specific T Cell Monitoring Offers Superior Risk Stratification of CMV-Seronegative Kidney Transplant Recipients of a CMV-Seropositive Donor. Transplantation, 2017, 101, e315-e325.	1.0	49
77	Comprehensive Approach for Identifying the T Cell Subset Origin of CD3 and CD28 Antibodyâ€“Activated Chimeric Antigen Receptorâ€“Modified T Cells. Journal of Immunology, 2017, 199, 348-362.	0.8	41
78	Everolimus with cyclosporine withdrawal or low-exposure cyclosporine in kidney transplantation from Month 3: a multicentre, randomized trial. Nephrology Dialysis Transplantation, 2017, 32, 1060-1070.	0.7	31
79	Unacceptable human leucocyte antigens for organ offers in the era of organ shortage: influence on waiting time before kidney transplantation. Nephrology Dialysis Transplantation, 2017, 32, 880-889.	0.7	15
80	Sepsis after renal transplantation: Clinical, immunological, and microbiological risk factors. Transplant Infectious Disease, 2017, 19, e12695.	1.7	22
81	Simultaneous pancreas/kidney transplant recipients are predisposed to tissueâ€invasive cytomegalovirus disease and concomitant infectious complications. Transplant Infectious Disease, 2017, 19, e12742.	1.7	7
82	Accelerating Patientsâ€™ Access to Advanced Therapies in the EU. Molecular Therapy - Methods and Clinical Development, 2017, 7, 15-19.	4.1	19
83	Vasodilation and Exercise Capacity in Patients with End-Stage Renal Disease: A Prospective Proof-of-Concept Study. CardioRenal Medicine, 2017, 7, 50-59.	1.9	4
84	Generation of a human induced pluripotent stem cell line from urinary cells of a healthy donor using integration free Sendai virus technology. Stem Cell Research, 2017, 21, 167-170.	0.7	4
85	Sequential Targeting of CD52 and TNF Allows Early Minimization Therapy in Kidney Transplantation: From a Biomarker to Targeting in a Proof-Of-Concept Trial. PLoS ONE, 2017, 12, e0169624.	2.5	10
86	T Cell PTLD Successfully Treated With Single-Agent Brentuximab Vedotin First-Line Therapy. Transplantation, 2016, 100, e8-e10.	1.0	13
87	Generation of a human induced pluripotent stem cell line from urinary cells of a healthy donor using an integration free vector. Stem Cell Research, 2016, 16, 314-317.	0.7	9
88	Kidney transplant recipients after nonrenal solid organ transplantation show low alloreactivity but an increased risk of infection. Transplant International, 2016, 29, 1296-1306.	1.6	7
89	Overcoming Challenges Facing Advanced Therapies in the EU Market. Cell Stem Cell, 2016, 19, 293-297.	11.1	114
90	Pretransplant prophylactic rituximab to prevent Epsteinâ€Barr virus (<scp>EBV</scp>) viremia in <scp>EBV</scp>â€seronegative kidney transplant recipients from <scp>EBV</scp>â€seropositive donors: results of a pilot study. Transplant Infectious Disease, 2016, 18, 881-888.	1.7	22

#	Article	IF	Citations
91	Simultaneous pancreas/kidney transplant recipients present with late-onset BK polyomavirus-associated nephropathy. Nephrology Dialysis Transplantation, 2016, 31, 1174-1182.	0.7	14
92	Putting a price tag on novel autologous cellular therapies. Cytotherapy, 2016, 18, 1056-1061.	0.7	32
93	Virus-specific T-cell therapy in solid organ transplantation. Transplant International, 2016, 29, 515-526.	1.6	14
94	Antibodies to Î² adrenergic and muscarinic cholinergic receptors in patients with Chronic Fatigue Syndrome. Brain, Behavior, and Immunity, 2016, 52, 32-39.	4.1	188
95	Effects of Treatment of Asymptomatic Hyperuricemia on Graft Survival and Mortality in Kidney Transplant Recipients. Annals of Transplantation, 2016, 21, 350-359.	0.9	11
96	Different risk factor profiles distinguish early-onset from late-onset BKV-replication. Transplant International, 2015, 28, 1081-1091.	1.6	32
97	ABO desensitization affects cellular immunity and infection control after renal transplantation. Transplant International, 2015, 28, 1179-1194.	1.6	25
98	Regulatory T cell-mediated anti-inflammatory effects promote successful tissue repair in both indirect and direct manners. Frontiers in Pharmacology, 2015, 6, 184.	3.5	122
99	Renal, efficacy and safety outcomes following late conversion of kidney transplant patients from calcineurin inhibitor therapy to everolimus: the randomized APOLLO study. Clinical Nephrology, 2015, 83 (2015), 11-21.	0.7	33
100	Gene therapy: a possible future standard for HIV care. Trends in Biotechnology, 2015, 33, 374-376.	9.3	8
101	Immunogenicity of allogeneic mesenchymal stromal cells: what has been seenin vitroandin vivo?. Regenerative Medicine, 2015, 10, 305-315.	1.7	54
102	Peripheral Bloodâ€“Derived Virus-Specific Memory Stem T Cells Mature to Functional Effector Memory Subsets with Self-Renewal Potency. Journal of Immunology, 2015, 194, 5559-5567.	0.8	36
103	Renal function to 5Âyears after late conversion of kidney transplant patients to everolimus: a randomized trial. Journal of Nephrology, 2015, 28, 115-123.	2.0	16
104	A revised strategy for monitoring BKV-specific cellular immunity in kidney transplant patients. Kidney International, 2015, 88, 1293-1303.	5.2	25
105	Risk-Stratified Cardiovascular Screening Including Angiographic and Procedural Outcomes of Percutaneous Coronary Interventions in Renal Transplant Candidates. Journal of Transplantation, 2014, 2014, 1-11.	0.5	5
106	FcÎ³-Receptor IIIA Polymorphism p.158F Has No Negative Predictive Impact on Rituximab Therapy with and without Sequential Chemotherapy in CD20-Positive Posttransplant Lymphoproliferative Disorder. Journal of Immunology Research, 2014, 2014, 1-6.	2.2	3
107	Inflammatory activation and recovering BKV-specific immunity correlate with self-limited BKV replication after renal transplantation. Transplant International, 2014, 27, 290-301.	1.6	33
108	The business case for cell and gene therapies. Nature Biotechnology, 2014, 32, 1192-1193.	17.5	28

#	Article	IF	Citations
109	Differential influenza H1N1-specific humoral and cellular response kinetics in kidney transplant patients. Medical Microbiology and Immunology, 2014, 203, 35-45.	4.8	21
110	Efficacy and safety of conversion from cyclosporine to everolimus in living-donor kidney transplant recipients: an analysis from the ZEUS study. Transplant International, 2014, 27, 1192-1204.	1.6	6
111	A roadmap toward clinical translation of genetically-modified stem cells for treatment of HIV. Trends in Molecular Medicine, 2014, 20, 632-642.	6.7	23
112	Deficient EBV-Specific B- and T-Cell Response in Patients with Chronic Fatigue Syndrome. PLoS ONE, 2014, 9, e85387.	2.5	82
113	Terminally Differentiated CD8 ⁺ T Cells Negatively Affect Bone Regeneration in Humans. Science Translational Medicine, 2013, 5, 177ra36.	12.4	250
114	To be, or not to be immunocompetent. Critical Care, 2013, 17, 185.	5.8	6
115	Impaired thymic function and CD4+ T lymphopenia, but not mannose-binding lectin deficiency, are risk factors for Pneumocystis jirovecii pneumonia in kidney transplant recipients. Transplant Immunology, 2013, 28, 159-163.	1.2	20
116	Good Manufacturing Practices (GMP) manufacturing of advanced therapy medicinal products: a novel tailored model for optimizing performance and estimating costs. Cytotherapy, 2013, 15, 362-383.	0.7	57
117	Prospective assessment of antidonor cellular alloreactivity is a tool for guidance of immunosuppression in kidney transplantation. Kidney International, 2013, 84, 1226-1236.	5.2	66
118	The genetic predisposition of natural killer cell to BK virusâ€“associated nephropathy in renal transplant patients. Kidney International, 2013, 84, 359-365.	5.2	39
119	Culture surface influence on T-cell phenotype and function. Clinical Hemorheology and Microcirculation, 2013, 55, 501-512.	1.7	3
120	HCMV-specific T-cell Therapy. Journal of Immunotherapy, 2013, 36, 93-101.	2.4	15
121	B-Cell-Related Biomarkers of Tolerance are Up-Regulated in Rejection-Free Kidney Transplant Recipients. Transplantation, 2013, 95, 148-154.	1.0	72
122	Preferential Expansion of Human Virus-Specific Multifunctional Central Memory T Cells by Partial Targeting of the IL-2 Receptor Signaling Pathway: The Key Role of CD4+ T Cells. Journal of Immunology, 2012, 188, 5189-5198.	0.8	22
123	Predicting the outcome of renal transplantation. Journal of the American Medical Informatics Association: JAMIA, 2012, 19, 255-262.	4.4	33
124	Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial. Lancet Oncology, The, 2012, 13, 196-206.	10.7	349
125	Mannose-binding lectin deficiency is not associated with increased risk for polyomavirus nephropathy. Transplant Immunology, 2012, 26, 123-127.	1.2	9
126	Absolute and functional iron deficiency in professional athletes during training and recovery. International Journal of Cardiology, 2012, 156, 186-191.	1.7	68

#	Article	IF	Citations
127	Burkitt postâ€transplantation lymphoma in adult solid organ transplant recipients. Cancer, 2012, 118, 4715-4724.	4.1	29
128	BK polyomavirus infection and nephropathy: the virusâ€“immune system interplay. Nature Reviews Nephrology, 2011, 7, 399-406.	9.6	100
129	Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet, The, 2011, 377, 837-847.	13.7	326
130	Novel Approach for Improved Assessment of Phenotypic and Functional Characteristics of BKV-Specific T-Cell Immunity. Transplantation, 2011, 92, 1269-1277.	1.0	46
131	BK-VP3 as a New Target of Cellular Immunity in BK Virus Infection. Transplantation, 2011, 91, 100-107.	1.0	51
132	Plasmacytoma-like post-transplant lymphoproliferative disorder, a rare subtype of monomorphic B-cell post-transplant lymphoproliferation, is associated with a favorable outcome in localized as well as in advanced disease: a prospective analysis of 8 cases. Haematologica, 2011, 96, 1067-1071.	3.5	61
133	IL-6 and IL-10 in post-transplant lymphoproliferative disorders development and maintenance: a longitudinal study of cytokine plasma levels and T-cell subsets in 38 patients undergoing treatment. Transplant International, 2011, 24, 892-903.	1.6	30
134	In vivo effect of bone marrow-derived mesenchymal stem cells in a rat kidney transplantation model with prolonged cold ischemia. Transplant International, 2011, 24, 1112-1123.	1.6	55
135	Monitoring tolerance and rejection in organ transplant recipients. Biomarkers, 2011, 16, S42-S50.	1.9	27
136	Renal Function, Efficacy, and Safety of Sirolimus and Mycophenolate Mofetil After Short-Term Calcineurin Inhibitor-Based Quadruple Therapy in De Novo Renal Transplant Patients: One-Year Analysis of a Randomized Multicenter Trial. Transplantation, 2010, 90, 175-183.	1.0	91
137	State of the art on the research for biomarkers allowing individual, tailor-made minimization of immunosuppression. Current Opinion in Organ Transplantation, 2010, 15, 691-696.	1.6	13
138	Human peripheral blood and bone marrow Epsteinâ€“Barr virusâ€specific Tâ€cell repertoire in latent infection reveals distinct memory Tâ€cell subsets. European Journal of Immunology, 2010, 40, 1566-1576.	2.9	32
139	Molecular Phenotypes of Acute Rejection Predict Kidney Graft Prognosis. Journal of the American Society of Nephrology: JASN, 2010, 21, 173-180.	6.1	28
140	High-Mobility Group Box-1 Protein Serum Levels Do Not Reflect Monocytic Function in Patients with Sepsis-Induced Immunosuppression. Mediators of Inflammation, 2010, 2010, 1-6.	3.0	5
141	Treatment with granulocyteâ€“macrophage colony-stimulating factor is associated with reduced indoleamine 2,3-dioxygenase activity and kynurenine pathway catabolites in patients with severe sepsis and septic shock. Scandinavian Journal of Infectious Diseases, 2010, 42, 164-171.	1.5	34
142	The Influence of Recovery and Training Phases on Body Composition, Peripheral Vascular Function and Immune System of Professional Soccer Players. PLoS ONE, 2009, 4, e4910.	2.5	39
143	Increased indoleamine 2,3-dioxygenase (IDO) activity and elevated serum levels of tryptophan catabolites in patients with chronic kidney disease: a possible link between chronic inflammation and uraemic symptoms. Nephrology Dialysis Transplantation, 2009, 24, 1901-1908.	0.7	207
144	Clonotype Analysis of Cytomegalovirus-Specific Cytotoxic T Lymphocytes. Journal of the American Society of Nephrology: JASN, 2009, 20, 344-352.	6.1	21

#	Article	IF	Citations
145	High levels of CMV-IE-1-specific memory T cells are associated with less alloimmunity and improved renal allograft function. Transplant Immunology, 2009, 20, 238-242.	1.2	74
146	Granulocyteâ€“Macrophage Colony-stimulating Factor to Reverse Sepsis-associated Immunosuppression. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 640-648.	5.6	540
147	Human Bone Marrow as a Source to Generate CMV-specific CD4+ T Cells With Multifunctional Capacity. Journal of Immunotherapy, 2009, 32, 907-913.	2.4	12
148	Lymphocyte markers and prediction of long-term renal allograft acceptance. Current Opinion in Nephrology and Hypertension, 2009, 18, 489-494.	2.0	13
149	Potent Early Immune Response After Kidney Transplantation in Patients of the European Senior Transplant Program. Transplantation, 2009, 87, 992-1000.	1.0	32
150	Anti-Human Leukocyte Antigen and Donor-Specific Antibodies Detected by Luminex Posttransplant Serve as Biomarkers for Chronic Rejection of Renal Allografts. Transplantation, 2009, 87, 1505-1513.	1.0	313
151	Can We Use Biomarkers and Functional Assays to Implement Personalized Therapies in Transplantation?. Transplantation, 2009, 87, 1595-1601.	1.0	26
152	Diagnostic value of T-cell monitoring assays in kidney transplantation. Current Opinion in Organ Transplantation, 2009, 14, 426-431.	1.6	24
153	Pretransplant immune risk assessment. Current Opinion in Organ Transplantation, 2009, 14, 650-655.	1.6	14
154	Generation of HCMV-specific T-cell Lines From Seropositive Solid-organ-transplant Recipients for Adoptive T-cell Therapy. Journal of Immunotherapy, 2009, 32, 932-940.	2.4	22
155	Sustained BK Viruria as an Early Marker for the Development of BKV-Associated Nephropathy: Analysis of 4128 Urine and Serum Samples. Transplantation, 2009, 88, 89-95.	1.0	85
156	Sequential Treatment with Rituximab and CHOP Chemotherapy in B-Cell PTLD - Moving Forward to a First Standard of Care: Results From a Prospective International Multicenter Trial.. Blood, 2009, 114, 100-100.	1.4	6
157	Interleukin-6 serum level assessment using a new qualitative point-of-care test in sepsis: A comparison with ELISA measurements. Clinical Biochemistry, 2008, 41, 893-898.	1.9	24
158	Relationship of Immunosuppression to Epsteinâ€“Barr Viral Load and Lymphoproliferative Disease in Pediatric Heart Transplant Patients. Journal of Heart and Lung Transplantation, 2008, 27, 100-105.	0.6	88
159	Sepsis: Time has come to focus on the later stages. Medical Hypotheses, 2008, 71, 203-208.	1.5	56
160	Circulating Alloreactive T Cells Correlate with Graft Function in Longstanding Renal Transplant Recipients. Journal of the American Society of Nephrology: JASN, 2008, 19, 1419-1429.	6.1	118
161	T Cell Response to the Cytomegalovirus Major Capsid Protein (UL86) Is Dominated by Helper Cells with a Large Polyfunctional Component and Diverse Epitope Recognition. Journal of Infectious Diseases, 2008, 197, 1455-1458.	4.0	17
162	Consider delayed immunosuppression into the concept of sepsis. Critical Care Medicine, 2008, 36, 3118.	0.9	36

#	Article	IF	Citations
163	Immunohistochemical Detection of Hypoxia-Inducible Factor-1Î± in Human Renal Allograft Biopsies. Journal of the American Society of Nephrology: JASN, 2007, 18, 343-351.	6.1	82
164	Generation of EBV-specific T Cells for Adoptive Immunotherapy: A Novel Protocol Using Formalin-fixed Stimulator Cells to Increase Biosafety. Journal of Immunotherapy, 2007, 30, 817-824.	2.4	13
165	Salvage Chemotherapy for Refractory and Relapsed Posttransplant Lymphoproliferative Disorders (PTLD) After Treatment With Single-Agent Rituximab. Transplantation, 2007, 83, 912-918.	1.0	70
166	Evidence for Genetic Susceptibility Towards Development of Posttransplant Lymphoproliferative Disorder in Solid Organ Recipients. Transplantation, 2007, 84, 387-391.	1.0	46
167	Short-Term Anti-CD4 Plus Anti-TNF-Î± Receptor Treatment in Allogeneic Small Bowel Transplantation Results in Long-Term Survival. Transplantation, 2007, 84, 639-646.	1.0	12
168	Salvage Therapy for Relapsed Posttransplant Lymphoproliferative Disorders (PTLD) With a Second Progression of PTLD After Upfront Chemotherapy: The Role of Single-Agent Rituximab. Transplantation, 2007, 84, 1708-1712.	1.0	34
169	A NOVEL SELECTIVE EXTRACORPOREAL INTERVENTION IN SEPSIS. Shock, 2007, 28, 418-425.	2.1	66
170	Sequential Treatment with Rituximab and CHOP Chemotherapy in B-Cell PTLD - A New Standard in Therapy?.. Blood, 2007, 110, 390-390.	1.4	6
171	Modified ELISPOT technique â€" Highly significant inverse correlation of post-Tx donor-reactive IFNÎ³-producing cell frequencies with 6 and 12Âmonths graft function in kidney transplant recipients. Transplant Immunology, 2006, 16, 232-237.	1.2	44
172	Treatment of solid organ transplant recipients with autologous Epstein Barr virusâ€"specific cytotoxic T lymphocytes (CTLs). Blood, 2006, 108, 2942-2949.	1.4	241
173	Epsteinâ€"Barr viral load in whole blood of adults with posttransplant lymphoproliferative disorder after solid organ transplantation does not correlate with clinical course. Annals of Hematology, 2006, 85, 478-484.	1.8	48
174	Identification of Dialysis Patients with Panel-Reactive Memory T Cells before Kidney Transplantation Using an Allogeneic Cell Bank. Journal of the American Society of Nephrology: JASN, 2006, 17, 573-580.	6.1	68
175	Up-regulation of HIF in experimental acute renal failure: Evidence for a protective transcriptional response to hypoxia. Kidney International, 2005, 67, 531-542.	5.2	152
176	CD31+ Naive Th Cells Are Stable during Six Months Following Kidney Transplantation: Implications for Post-transplant Thymic Function. American Journal of Transplantation, 2005, 5, 1764-1771.	4.7	19
177	Effect of Anti-CD 20 Antibody Rituximab in Patients with Post-Transplant Lymphoproliferative Disorder (PTLD). American Journal of Transplantation, 2005, 5, 2901-2906.	4.7	237
178	HLA type-independent generation of antigen-specific Tâ€„cells for adoptive immunotherapy. European Journal of Immunology, 2005, 35, 2250-2258.	2.9	33
179	Protection from cytomegalovirus after transplantation is correlated with immediate early 1â€"specific CD8 T cells. Journal of Experimental Medicine, 2005, 201, 1031-1036.	8.5	336
180	Monitoring Temporary Immunodepression by Flow Cytometric Measurement of Monocytic HLA-DR Expression: A Multicenter Standardized Study. Clinical Chemistry, 2005, 51, 2341-2347.	3.2	224

#	Article	IF	Citations
181	FTY720 Prevents Anti-CD4 mAb-Induced Tolerance but Cannot Reverse Established Tolerance in a Rat Kidney Transplantation Model. American Journal of Transplantation, 2004, 4, 863-871.	4.7	6
182	ENHANCED GRANULYSIN mRNA EXPRESSION IN URINARY SEDIMENT IN EARLY AND DELAYED ACUTE RENAL ALLOGRAFT REJECTION. Transplantation, 2004, 77, 1866-1875.	1.0	97
183	Enzyme-Linked Immunosorbent Spot Assay for Donor-Reactive Interferon-Gamma-Producing Cells Identifies T-Cell Presensitization and Correlates with Graft Function at 6 and 12 Months in Renal-Transplant Recipients. Transplantation, 2004, 78, 1640-1646.	1.0	136
184	Treatment of Cytomegalovirus Disease with Valganciclovir in Renal Transplant Recipients: A Single Center Experience. Transplantation, 2004, 78, 283-285.	1.0	28
185	Old-for-Old Kidney Allocation Allows Successful Expansion of the Donor and Recipient Pool. American Journal of Transplantation, 2003, 3, 1434-1439.	4.7	111
186	Serine proteinase inhibitor-9, an endogenous blocker of granzyme B/perforin lytic pathway, is hyperexpressed during acute rejection of renal allografts. Transplantation, 2003, 75, 1565-1570.	1.0	72
187	Alterations of the immune response with increasing recipient age are associated with reduced long-term organ graft function of rat kidney allografts1. Transplantation, 2003, 76, 1560-1568.	1.0	27
188	Cytomegalovirus (CMV) Phosphoprotein 65 Makes a Large Contribution to Shaping the T Cell Repertoire in CMVâ€Exposed Individuals. Journal of Infectious Diseases, 2002, 185, 1709-1716.	4.0	260
189	Autologous Epstein-Barr virus (EBV)â€“specific cytotoxic T cells for the treatment of persistent active EBV infection. Blood, 2002, 100, 4059-4066.	1.4	141
190	Cytomegalovirus infections in kidney transplant patients. Transplantation Reviews, 2002, 16, 121-130.	2.9	0
191	RAPID DECLINE OF ANTIBODIES AFTER HEPATITIS A IMMUNIZATION IN LIVER AND RENAL TRANSPLANT RECIPIENTS. Transplantation, 2001, 71, 477-479.	1.0	95
192	ASSOCIATION BETWEEN EPSTEIN-BARR VIRUS INFECTION AND LATE ACUTE TRANSPLANT REJECTION IN LONG-TERM TRANSPLANT PATIENTS1. Transplantation, 2001, 72, 736-739.	1.0	33
193	CYTOTOXIC EFFECTOR MOLECULE GENE EXPRESSION IN ACUTE RENAL ALLOGRAFT REJECTION. Transplantation, 2001, 72, 1158-1161.	1.0	36
194	Analysis of CD8 T cell reactivity to cytomegalovirus using protein-spanning pools of overlapping pentadecapeptides. European Journal of Immunology, 2000, 30, 1676-1682.	2.9	255
195	Title is missing!. Molecular and Cellular Biochemistry, 2000, 212, 45-50.	3.1	37
196	A Novel Link between Stress and Human Cytomegalovirus (HCMV) Infection: Sympathetic Hyperactivity Stimulates HCMV Activation. Virology, 2000, 272, 357-365.	2.4	132
197	Measurement of Anti-Human Cytomegalovirus T Cell Reactivity in Transplant Recipients and Its Potential Clinical Use: A Mini-Review. Intervirology, 1999, 42, 322-324.	2.8	30
198	Immunogenicity and Safety of Hepatitis A Vaccine in Liver and Renal Transplant Recipients. Journal of Infectious Diseases, 1999, 180, 2014-2017.	4.0	102

#	Article	IF	Citations
199	Immunological monitoring of the inflammatory process: which variables? when to assess?. The European Journal of Surgery, 1999, 165, 70-72.	0.9	40
200	Distribution of human CMV-specific memory T cells among the CD8pos. subsets defined by CD57, CD27, and CD45 isoforms. European Journal of Immunology, 1999, 29, 2908-2915.	2.9	142
201	Human Cytomegalovirus Reactivation in Bone-Marrow-Derived Granulocyte/Monocyte Progenitor Cells and Mature Monocytes. Intervirology, 1999, 42, 308-313.	2.8	39
202	Target Structures of the CD8⁺-T-Cell Response to Human Cytomegalovirus: the 72-Kilodalton Major Immediate-Early Protein Revisited. Journal of Virology, 1999, 73, 8179-8184.	3.4	262
203	T-cell epitope mapping by flow cytometry. Nature Medicine, 1998, 4, 975-978.	30.7	273
204	Pentoxifylline Promotes Replication of Human Cytomegalovirus In Vivo and In Vitro. Blood, 1997, 89, 3682-3690.	1.4	23
205	Colour-coded duplex sonography in the diagnostic assessment of vascular complications after kidney transplantation in children. Pediatric Radiology, 1997, 27, 898-902.	2.0	24
206	Short-term Hemodynamic Effects of Immunoadsorption in Dilated Cardiomyopathy. Circulation, 1997, 95, 1994-1997.	1.6	143
207	Pentoxifylline Promotes Replication of Human Cytomegalovirus In Vivo and In Vitro. Blood, 1997, 89, 3682-3690.	1.4	26
208	DELAYED-TYPE HYPERSENSITIVITY-LIKE MECHANISMS DOMINATE LATE ACUTE REJECTION EPISODES IN RENAL ALLOGRAFT RECIPIENTS1,2. Transplantation, 1996, 61, 1233-1240.	1.0	37
209	Late-acute renal allograft rejection and symptomless cytomegalovirus infection. Lancet, The, 1995, 345, 794.	13.7	2
210	QUANTITATIVE PCR ANALYSIS OF CYTOKINE TRANSCRIPTION PATTERNS IN PERIPHERAL MONONUCLEAR CELLS AFTER ANTI-CD3 REJECTION THERAPY USING TWO NOVEL MULTISPECIFIC COMPETITOR FRAGMENTS1. Transplantation, 1994, 58, 264-267.	1.0	69
211	LATE ACUTE REJECTION IN LONG-TERM RENAL ALLOGRAFT RECIPIENTS. Transplantation, 1994, 58, 35-41.	1.0	39
212	CYTOMEGALOVIRUS INFECTION IN TRANSPLANT RECIPIENTS THE ROLE OF TUMOR NECROSIS FACTOR. Transplantation, 1994, 58, 675-680.	1.0	173
213	Tacrolimus CYP3A Single-Nucleotide Polymorphisms and Preformed T- and B-Cell Alloimmune Memory Improve Current Pretransplant Rejection-Risk Stratification in Kidney Transplantation. Frontiers in Immunology, 0, 13, .	4.8	0